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Abstract
Background: The EuroCMR registry sought to evaluate indications, image quality, safety and impact on patient
management of clinical routine CMR in a multi-national European setting. Furthermore, interim analysis of the specific
protocols should underscore the prognostic potential of CMR.
Methods: Multi-center registry with consecutive enrolment of patients in 57 centers in 15 countries. More than 27000
consecutive patients were enrolled.
Results: The most important indications were risk stratification in suspected CAD/Ischemia (34.2%), workup of
myocarditis/cardiomyopathies (32.2%), as well as assessment of viability (14.6%). Image quality was diagnostic in more
than 98% of cases. Severe complications occurred in 0.026%, always associated with stress testing. No patient died during
or due to CMR. In 61.8% CMR findings impacted on patient management. Importantly, in nearly 8.7% the final diagnosis
based on CMR was different to the diagnosis before CMR, leading to a complete change in management. Interim analysis
of suspected CAD and risk stratification in HCM specific protocols revealed a low rate of adverse events for suspected
CAD patients with normal stress CMR (1.0% per year), and for HCM patients without LGE (2.7% per year).
Conclusion: The most important indications in Europe are risk stratification in suspected CAD/Ischemia, work-up of
myocarditis and cardiomyopathies, as well as assessment of viability. CMR imaging is a safe procedure, has diagnostic
image quality in more than 98% of cases, and its results have strong impact on patient management. Interim analyses of
the specific protocols underscore the prognostic value of clinical routine CMR in CAD and HCM.
Condensed abstract
The EuroCMR registry sought to evaluate indications, image quality, safety and impact on patient management of
clinical routine CMR in a multi-national European setting in a large number of cases (n > 27000). Based on our data
CMR is frequently performed in European daily clinical routine. The most important indications in Europe are risk
stratification in suspected CAD/Ischemia, work-up of myocarditis and cardiomyopathies, as well as assessment of
viability. CMR imaging is a safe procedure, has diagnostic image quality in more than 98% of cases, and its results
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have strong impact on patient management. Interim analyses of the specific protocols underscore the prognostic
value of clinical routine CMR in CAD and HCM.
Keywords: Cardiovascular magnetic resonance, Registry, Quality, Safety, Therapeutic implications, Impact, Patient
management
Background
The German pilot phase of the EuroCMR Registry con-
cluded on the basis of 11040 consecutive patients from
20 German centers that CMR is frequently performed in
German clinical practice [1]. The most important indica-
tions in Germany were work-up of myocarditis/cardiomyo-
pathies, risk stratification in suspected CAD/Ischemia, and
assessment of viability. Furthermore, the registry data
indicated that CMR imaging as used in the centers of the
German pilot registry was a safe procedure, had diagnostic
image quality in 98% of cases, and its results had strong im-
pact on patient management.
In the meantime more than 27000 consecutive patients
from 57 European centers in 15 countries have been
included in the EuroCMR Registry. With the current ana-
lysis we sought to evaluate indications, image quality, safety,
and impact on patient management of routine CMR im-
aging on a European level. Specifically we aim to demon-
strate that the results of the German pilot data [1] hold
true in this much larger multi-national and multi-ethnical
population. In addition, interim analysis of the specific pro-
tocols initiated on the basis of the German pilot data
should underscore the prognostic potential of CMR in
certain indications, such as risk stratification in suspected
CAD and hypertrophic cardiomyopathy [1,2] in a multi-
national clinical routine setting.
Methods
Study population and data management
The basis of the current manuscript is the EuroCMR
registry. This registry includes 27781 consecutive CMR
scans from 27301 consecutive patients undergoing
CMR according to the ACCF/ACR/SCCT/SCMR/ASNC/
NASCI/SCAI/SIR consensus appropriateness criteria for
CMR imaging [3] in 57 participating sites in 15 European
countries (Figure 1). All procedures were in compliance
with the standardized SCMR recommended protocols [4].
All data were prospectively collected by trained personnel,
manually entered in online case record forms provided by
the “Institut für Herzinfarktforschung”, University of
Heidelberg, Germany (www.herzinfarktforschung.de) via a
SSL-secured internet connection, and stored on a central
server. Each participating center appointed a senior investi-
gator (either SCMR or EuroCMR level 3 trained, or
licensed for CMR by the local chamber of physicians, which
e.g. in Germany has stricter requirements than SCMR level
Figure 1 Political map of Europe visualizing all 57 participating centers in 15 countries.
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3 (two years full time training)) as local investigator respon-
sible for data quality of each patient entered. If necessary,
this local investigator contacted all sources of information
necessary in order to determine more complex variables,
such as the impact of CMR on patient management. A
plausibility check was carried out after submitting the data
to minimize further queries. Benchmarking reports were
regularly made available to the local investigators for quality
control. Local ethics committees approved data collection
and management for every center.
Analysis cohort
All 27781 CMR scans enrolled until June 2012 were
included in the analysis. The completeness of the analysis
dataset was higher than 98%. For some types of analysis the
cohort was divided in patients that underwent CMR stress
testing (n = 10228, including patients with suspected as well
as with known CAD), and patients that did not undergo
stress CMR (n = 17136). Some patients were also part of a
previous report [1].
Variables, definitions and endpoints
All variables assessed were pre-defined, and were collected
directly from patients, and/or from medical records. Vari-
ables include anonymized demographic data, history, indi-
cation for CMR, procedural parameters, complications,
results of CMR, the impact of CMR on clinical manage-
ment, as well as clinical follow-up data for patients included
in the specific protocols. Many fields are self-explanatory,
all other fields (including follow-up end points for specific
protocols) are defined and described in previous publica-
tions [1,2]. In case of a suspected event [2], all necessary
medical records were obtained and reviewed by members
of the steering committee acting as endpoint committee.
Statistics
Since the objectives of this registry are descriptive in
nature, no formal hypothesis testing was done. Absolute
numbers and percentages were computed to describe
the patient population. Medians (with quartiles) or
means (with standard deviation) were computed as
appropriate. Categorical values were compared by
chi-square test or Fisher’s exact test and continuous
variables were compared by two-tailed Wilcoxon rank
sum test. The Cochrane-Armitage test was used for ana-
lyzing trends regarding age groups. P-values <0.05 were
considered significant. Kaplan Meier curves were calcu-
lated for visualizing the cumulative survival free of
events of patients with normal and several abnormal
CMR results. Log-rank tests were performed to compare
survival curves. All p-values were results of two-tailed
tests. The tests were performed using the SAS© statis-
tical package, version 9.1 (SAS, Cary, North Carolina).
Results
General use of CMR in the European clinical routine and
most important indications
The most important indications for CMR in Europe
were 1) risk stratification in suspected CAD/Ischemia in
known CAD (34.2%), 2) work-up of myocarditis and car-
diomyopathies (32.2%), followed by 3) the assessment of
myocardial viability (14.6%). Ninety-two percent of all
patients received a gadolinium based contrast agent.
Baseline characteristics can be viewed in Table 1.
Procedural safety in the European clinical routine
Nearly 97% of all CMR procedures (n = 27781) were
performed without complications. Mild complications
occurred in 3.6% of patients (n = 994), and severe
Table 1 Baseline characteristics
N or quartiles
All 100% 27781
Male 65.5% 17841/27249
Female 34.5% 9408/27249
Age (yrs) 60.0 47.0 - 70.0
BMI (kg/m2) 26.2 23.7 - 29.3
Field
1.0-T 0.5% 134/27669
1.5-T 93.6% 25899
3.0-T 5.9% 1636
Stress
No stress 62.6% 17158/27395
Adenosine 29.3% 8018
Dobutamine 8.1% 2219
Reader
Cardiologist 70.7% 19589/27703
Team of cardiologist and radiologist 26.7% 7398
Radiologist 2.6% 716
Primary indication for CMR
Myocarditis/cardiomyopathies 32.2% 8950/27767
Suspected CAD/ischemia in known CAD 34.2% 9508
Myocardial viability 14.6% 4048
Valvular heart disease 5.4% 1495
Aortic disease 3.7% 1026
Congential heart disease 2.2% 624
Ventricular thrombus 1.2% 330
Cardiac masses 1.0% 288
Pulmonary vessels 1.0% 282
Coronary vessels 0.2% 57
Other than above 10.7% 2963
Values are % (n) or mean (standard deviation).
BMI Body mass Index.
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complications in 0.026% only (n = 7). In the group with
mild complications most events (e.g. dyspnea, chest
pain, extra systoles, etc.) occurred during dobutamine
or adenosine infusion (75%), followed by mild allergic
reactions after injection of contrast (e.g. mild urticaria
or exanthema) in 5% of cases.
In the 7 patients with severe complications we found
non-sustained VT (n = 2) and ventricular fibrillation (n = 1)
during dobutamine infusion, as well as overt heart failure
(n = 2), unstable angina (n = 1), and anaphylactic shock
(n = 1) in the setting of adenosine stress. All severe compli-
cations were related to stress testing (Table 2). Procedural
safety was not dependent on gender, age of the patient, the
country or the center the scan was performed.
Image quality in the European clinical routine
Good image quality was achieved in 88.0% (n = 24094) of
patients. In 10.3% (n = 2817) image quality was moderate
but still diagnostic. Poor image quality (non-diagnostic)
was present in 1.7% of patients only (n = 451). No relevant
difference was found comparing stress to no stress CMR
(good image quality in 87.2% without stress vs. 89.5% with
stress).
Image quality was not dependent on gender of the
patients, nor the country or the center the scan was per-
formed. However, there was a significant trend towards
poorer image quality in older patients (>75 yrs vs. <45 yrs;
p < 0.0001). Despite this decrease of image quality with age,
the ability of CMR to derive a diagnosis and the impact on
patient management was not affected (Table 3). In fact, the
percentage of therapeutic consequences was even higher in
older patients compared to younger patients (>75 yrs vs.
<45 yrs; p < 0.0001).
Impact of CMR on patient management in the European
clinical routine
In nearly two thirds of all patients (61.8%) we could
demonstrate direct impact of CMR on the clinical man-
agement by providing an unsuspected new diagnosis
(8.7%) and/or resulting in therapeutic consequences as
described in Table 4. Table 5 demonstrates the impact
on patient management by indication for the three most
common CMR indications as described above.
Focusing on the group of patients that underwent
stress CMR for work-up of suspected CAD or suspected
ischemia in known CAD reveals that in nearly half the
cases (45%) invasive angiography could be avoided based
on the results of CMR (Table 6).
Interim analysis of the first two specific protocols
Specific protocol - suspected CAD
The main aim of this specific EuroCMR Registry proto-
col is to demonstrate that patients presenting for
workup of suspected CAD, which have a completely nor-
mal CMR scan, will have a low risk for adverse cardio-
vascular events during follow-up in a multi-national
clinical routine setting. A detailed description of this
protocol including the definitions of variables and ad-
verse events has been published previously [2].
At the end of June 2012 more than 3300 patients have
been enrolled in this specific protocol, which is still open
for ongoing recruitment. Clinical follow-up data (mean
400d, IQR 367d-419d, follow-up rate 90%) is currently
available for 1706 patients. In the subgroup of patients
with normal CMR (n = 866, defined as LV-EF ≥ 60% and
LV-EDV ≤ 180 ml and no ischemia and no LGE) the rate
of major adverse events (all cause death, aborted SCD,
or non-fatal myocardial infarct [2]) was 1.0% per year
during follow-up. In the group with abnormal CMR
(n = 840, defined as LV-EF < 60% or LV-EDV > 180 ml or
ischemia or LGE) the event rate was 2.7% per year, see
Figure 2.
Specific protocol - risk stratification in HCM
The main aim of this specific EuroCMR Registry proto-
col is to establish the role of LGE in risk stratification of
HCM patients with regard to cardiac death. Specifically
we sought to confirm that the presence of LGE is an in-
dependent risk factor for cardiac death and other ad-
verse events in HCM patients. A detailed description of
this protocol has also been published previously [2].
At the end of June 2012 more than 550 patients have
been enrolled in this specific protocol, which is also still
open for ongoing recruitment. Clinical follow-up data
(mean 409d, IQR 372d-437d, follow-up rate 90%) is cur-
rently available for 249 patients. In the subgroup of
patients without LGE (n = 115) the rate of major adverse
events (all cause death, aborted SCD, or adequate ICD
discharge [2]) was 2.2% per year during follow-up. In the
Table 2 Complications related to no stress vs. stress CMR
All (n = 27396) No stress (n = 17136) Stress (n = 10228)
Complications
None 96.3% (n = 26395) 98.6% (n = 16893) 92.6% (n = 9476)
Mild 3.6% (n = 994) 1.4% (n = 243) 7.3% (n = 745)
Severe 0.0% (n = 7) 0.0% (n = 0) 0.1% (n = 7)
Values are % (n).
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group with any LGE present in the myocardium
(n = 134), the event rate was 4.3% per year, see Figure 3.
Discussion
This dataset is unique in that it describes the clinical
use, including indications, image quality, procedural
safety and impact on patient management of CMR in
more than 27000 patients from 57 centers in 15 coun-
tries (see Additional file 1: Data supplement). Our data
confirm pilot results [1] indicating that CMR is fre-
quently performed in clinical routine, is a safe proced-
ure, has diagnostic image quality in more than 98% of
cases, and its results have strong impact on patient man-
agement. Furthermore, interim analyses underscore the
prognostic potential of CMR in the clinical routine.
General use of CMR in the European clinical routine and
most important indications
Similar to our pilot data, more than 92% of CMR proce-
dures involved the use of Gadolinium based contrast
media, allowing the detection of small subendocardial
infarcts [5,6], prediction of recovery of ventricular func-
tion before revascularisation [7], risk stratification in
suspected coronary artery disease [8,9], evaluation of
myocardial ischemia [10], as well as assessment of cardi-
omyopathies [11], and myocarditis [12-14], respectively.
In line with pilot phase results [1], CMR case reading and
reporting was done by cardiologists (70.7%), a team of car-
diologists and radiologists (26.7%), or radiologists alone
(2.6%). This finding may be influenced by a selection bias,
since the registry was initiated and is run by a cardiologist
society. However, we did not find significant differences in
image quality, safety or impact on patient management
comparing those three reading/reporting groups.
In comparison to the pilot data however, the clinical rou-
tine use of CMR imaging at 3 Tesla increased from 0.8% to
5.9% in the current dataset. This may be explained by
advantages of 3 Tesla compared to 1.5 Tesla, such as
improved speed (e.g. CMR perfusion), and/or spatial reso-
lution [15,16].
Procedural safety in the European clinical routine
Mild complications occurred in 3.6%, and severe complica-
tions in 0.026% of patients only. No patient died during or
due to CMR, confirming that CMR is safe when performed
in a multi-national routine clinical setting. All severe com-
plications were related to stress testing (Table 2), in line
with the German pilot results [1]. Importantly, the proced-
ural safety of CMR is not dependent on race, gender or age
Table 3 Indications, image quality, and complications related to patient age
≤44 yrs 45 – 59 yrs 60 – 74 yrs ≥75 yrs
Indication
Ischemia/CAD 12.1% 37.7% 48.1% 49.5%
Myocarditis/CMP 63.6% 36.6% 22.5% 16.5%
Viability 5.3% 17.0% 19.2% 22.4%
Stress CMR 13.7% 38.0% 47.5% 47.9%
Image quality
Good 92.6% 90.8% 86.2% 80.1%
Moderate 6.3% 8.0% 11.9% 16.9%
Poor 1.1% 1.2% 1.9% 3.0%
Complications
None 98.4% 96.7% 95.5% 94.4%
Mild 1.6% 3.3% 4.5% 5.5%
Severe 0.0% 0.1% 0.0% 0.0%
New diagnosis 9.3% 9.5% 8.7% 7.7%
Therapeutic consequence 40.4% 51.9% 58.4% 64.6%
Table 4 Impact of CMR on patient management
N or quartiles
All 100% 27781
Completely new diagnosis not
suspected before
8.7% 2354/27006
Therapeutic consequences
Change in medication 25.0% 6689/26743
Invasive procedure 16.8% 4510/26778
Hospital discharge 10.2% 2738/26771
Hospital admission 1.4% 386/26780
Impact on patient management (new
diagnosis and/or therapeutic consequence)
61.8% 16677/27006
Values are % (n).
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of patients, despite a much greater racial diversity in the
current European dataset.
However, one important limitation of our data concern-
ing CMR safety may be that not all EuroCMR Registry
patients undergo systematic clinical follow-up (specific pro-
tocols only, [2]) and thus, theoretically possible cases of
NSF may have been missed. However, we did not receive
any reports of NSF from the patients undergoing clinical
follow-up in one of the specific protocols. Nevertheless,
serum creatinine and glomerular filtration rate should be
evaluated and taken into account prior to any gadolinium
contrast administration.
Since most complications of stress CMR are not related
to CMR imaging itself, but to stressing the patient, stress
CMR has been confirmed to be at least as safe as stress
echocardiography [17], stress nuclear testing [18], or even
as safe as obtaining a simple treadmill ECG (about one fatal
complication or myocardial infarct in 2500 cases) [19].
Image quality in the European clinical routine
To our knowledge, this is the first dataset on clinical rou-
tine image quality of CMR in a European setting. Our data
demonstrate that CMR is capable of answering the relevant
clinical questions in more than 98% of cases. This indicates,
that current CMR utilisation yields a high number of valu-
able studies, most probably related to the good image qual-
ity. Only 1.7% of studies were inadequate in quality,
allowing no diagnosis.
Importantly, this was shown in a multi-national, multi-
ethnical consecutive clinical routine setting, including all
comers such as patients with dyspnea at rest, atrial
fibrillation, obesity (body mass index quartiles 23.7-29.3 kg/
m2), or other frequent cardiac conditions affecting image
quality. Thus, the average image quality of CMR in the clin-
ical routine is better than the average image quality of other
non-invasive imaging techniques, such as echocardiography
[20], cardiac CT [21,22], or SPECT [23]. In addition, no
ionising radiation is needed for CMR, which can therefore
be repeated as often as necessary for follow-up purposes.
Matching our German pilot data [1], we found a sig-
nificant decrease of image quality in older patients,
which again was associated with an increased impact on
patient management in this group (Table 3). This can be
explained by the higher morbidity in older patients caus-
ing more gating or breathing problems, but on the other
hand yielding more abnormal findings requiring an
altered management (Table 3).
Impact of CMR on patient management in the European
clinical routine
CMR had direct impact on the clinical management of
the majority of patients (Tables 4 and 5), also confirming
the earlier German pilot results [1] in the European clin-
ical routine. In patients undergoing CMR stress testing
for work-up of CAD (Table 6) invasive angiography
could be avoided in nearly half the patients (n = 4555),
underscoring the role of CMR stress testing as a gate-
keeper for invasive angiography. In addition, nearly 6148
non-invasive procedures involving the use of ionizing ra-
diation, such as SPECT imaging could also be avoided
on the basis of the CMR results (Table 6).
We did not yet perform a cost analysis of integrating
CMR into the clinical routine at a European level.
Table 5 Impact of CMR on patient management by indication
Myocarditis/CMP Suspected CAD/Ischemia Viability
All (from n = 27781) 32.2% 34.2% 14.6%
Completely new diagnosis not suspected before 11.4% 8.1% 5.3%
Therapeutic consequences
Change in medication 25.3% 24.3% 33.2%
Invasive procedure 6.9% 23.1% 24.2%
Hospital discharge 10.4% 14.3% 6.9%
Hospital admission 1.1% 1.5% 1.9%
Impact on patient management (new diagnosis and/or therapeutic consequence) 55.1% 71.4% 71.5%
Table 6 Additional diagnostic procedures avoided due to results of CMR
All (n = 27025) No stress (n = 16526) Stress (n = 10113)
Invasive angiography 24% (n = 6483) 11.6% (n = 1921) 45% (n = 4555)
Nuclear (SPECT/PET) 20.6% (n = 5574) 9.8% (n = 1624) 39% (n = 3946)
Coronary CT 11.8% (n = 3182) 5.9% (n = 976) 21.8% (n = 2202)
Values are % (n).
PET Positron emission tomography.
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However, a cost effectiveness analysis performed on the
basis of the German pilot data [1] indicates that integrat-
ing CMR in the clinical routine does not increase the
overall costs of patient care, but reduces costs between
11% and 65% in most cases [24].
Interim analysis of the first two specific protocols
Specific protocol - suspected CAD
Our current interim data indicate a rate of major adverse
events (all cause death, aborted SCD, or non-fatal myocar-
dial infarct [2]) of 1.0% per year for patients with normal
Kaplan-Meier Survival Curves:   Protocol Suspected CAD 
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Figure 2 Kaplan-Meier Survival Curves for the specific protocol “suspected CAD” with regard to death, aborted SCD and non-fatal
myocardial infarction. The number of patients at risk is shown at the bottom of the figure.
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stress CMR in the group of 1706 patients that underwent
12-month follow-up in this specific protocol so far
(Figure 2). This confirms the results of earlier controlled
studies in smaller (often single-center) populations [25-27]
in a multi-national and multi-ethnical clinical routine set-
ting, underscoring the prognostic value of clinical routine
CMR for this indication.
Specific protocol - risk stratification in HCM
On the basis of 249 patients that have undergone
12-month follow-up so far, we already found a trend
towards better outcome in HCM patients without LGE
(Figure 3), also confirming the results of earlier controlled
single center studies [28,29] in a multi-national clinical rou-
tine setting, and almost exactly matching the calculated
event rates of a recent meta analysis [30]. However, in the
studies mentioned above the mean follow-up time was
much longer (median more that 3 years) then in this regis-
try protocol so far (just 12-month), which most likely
explains why the trend in the registry data does not yet
reach statistical significance.
Conclusion
The current EuroCMR Registry data including more
than 27000 patients from 57 centers in 15 countries con-
firm that CMR is frequently performed in European
daily clinical practice. The most important indications in
Europe are risk stratification in suspected CAD/Ische-
mia, work-up of myocarditis and cardiomyopathies, as
well as assessment of myocardial viability. CMR imaging
as used in the centres of the EuroCMR Registry, is a safe
procedure, has diagnostic image quality in more than
98% of cases, and its results have strong impact on pa-
tient management. Interim analyses of the specific pro-
tocols underscore the prognostic value of clinical
routine CMR in HCM and suspected CAD in a multi-
national clinical routine setting.
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